Cart
sales@molnova.com
LJI308
CAS No. 1627709-94-7
LJI308 ( LJI308; LJI-308; LJI 308; NVP-LJI308; NVP-LJI-308 )
Catalog No. M17345 CAS No. 1627709-94-7
LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 73 | In Stock |
|
| 10MG | 88 | In Stock |
|
| 25MG | 203 | In Stock |
|
| 50MG | 316 | In Stock |
|
| 100MG | 486 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLJI308
-
NoteResearch use only, not for human use.
-
Brief DescriptionLJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
-
DescriptionLJI308 is a RSK inhibitor. LJI308 overcomes chemoresistance by eliminating cancer stem cells. LJI308 targets the CSC population and repress TNBC growth and dissemination. LJI308 specifically targeted transformed cells as it had little effect on the non-tumorigenic parental HMECs. Targeting RSK using specific and potent inhibitors, such as LJI308, delivers the promise of inhibiting the growth of TNBC.
-
SynonymsLJI308; LJI-308; LJI 308; NVP-LJI308; NVP-LJI-308
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorRSK1;RSK2;RSK3
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1627709-94-7
-
Formula Weight368.38
-
Molecular FormulaC21H18F2N2O2
-
Purity98%
-
SolubilityDMSO : ≥ 32 mg/mL 86.87 mM
-
SMILESOc1c(F)cc(cc1F)-c1cnccc1-c1ccc(cc1)N1CCOCC1
-
Chemical Name2,6-Difluoro-4-[4-[4-(4-morpholinyl)phenyl]-3-pyridinyl]-phenol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Aronchik I, Appleton B A, Basham S E, et al. Molecular Cancer Research, 2014, 12(5): 803-812.
molnova catalog
related products
-
TP-10
TP-10 is a selective inhibitor of PDE10A against other PDEs with IC50 of 0.8 nM.
-
Ensifentrine
Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.
-
FCPR03
FCPR03 is a selective inhibitor of phosphodiesterase 4 (PDE4) with IC50s of 31 nM, 47 nM, and 60 nM for PDE4B1, PDE4D7, and PDE4 catalytic domain, respectively.
